Impact Factor
2.62
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.70
193 total citations
h5-index
20
h5 depth signal
Cited share
36.5%
42 of 115
Total citations
193
Citation footprint
Metric signal
1.17
External metric anchor
Self-citation
0.5%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Germany
407
United States
59
Switzerland
53
Japan
38
Canada
32
Citing Fields of Research
Psychiatry
451
Neurosciences
136
Substance Abuse
88
Brain Neurological Disorders
56
Pharmacology & Toxicology
53
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,972
Articles tracked across the journal lifetime
Indexed publication set
115
42 cited publications
Last 12 months
39
3.5 publications/month
Open access share
30.8%
12 OA publications in the last year
Leading citing country
Germany
407 citing publications
Leading citing field
Psychiatry
451 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v17n1,Jan. 1984-
v17n1,Jan. 1984-
Active Coverage
Research Focus & Classification
Indexed Subjects
Psychiatry
Broad Categories
Psychiatry
Psychopharmacology
Psychiatry
Substance Abuse
Neurosciences
Neurodegenerative Disorders
MeSH Descriptors
Neurophysiology
Psychology, Clinical
Psychopharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1055/a-2975-2221
Open DOI
Single-Item Anhedonia in Schizophrenia Marks Illness Severity but Does Not Independently Predict Outcomes: An Item-Level Reanalysis of the Clinical Antipsychotic Trials of Intervention Effectiveness Trial
Anhedonia has been proposed as a marker of poor functional outcomes in schizophrenia. A model that omits baseline functioning estimates a different quantity from one that includes it: the former assesses whether anhedonia identifies pati...
02
DOI 10.1055/a-2959-4334
Open DOI
Changes in Weight and Metabolic Indices after Switching to Aripiprazole Once-Monthly in Patients with Schizophrenia According to Prior Oral Antipsychotics
Antipsychotic-induced weight gain and metabolic disturbance are common in schizophrenia, but liability varies across agents. Aripiprazole has a relatively favorable metabolic profile, yet evidence on aripiprazole once-monthly, its long-a...
03
DOI 10.1055/a-2959-4626
Open DOI
Effects of Repeated Ketamine Infusions on Suicidal Ideation in Treatment-Resistant Depression and Associated Changes in Selected Plasma Biomarkers
This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to i...
04
DOI 10.1055/a-2949-6177
Open DOI
Mood rhythms and circadian medicine for mood disorders
In this review, a comprehensive overview of the brain regions, neurotransmitters and hormones involved in mood and emotions is provided. Their relevance to rhythmic changes in mood is highlighted and vice versa the influence of the circa...
05
DOI 10.1055/a-2934-0429
Open DOI
Mood destabilizers?: A review of mood stabilizer-associated mania
Mania is associated with significant morbidity and mortality. Mood stabilizing medications are typically used to prevent manic episodes, yet in some cases can precipitate them. The literature on this rare but potentially serious paradoxi...
06
DOI 10.1055/a-2935-8784
Open DOI
Effects of Etifoxine and Alprazolam on Pregnenolone, Cortisol, and 18-kDa Translocator Protein in Healthy Men: A Placebo-Controlled Study
Introduction: The non-benzodiazepine anxiolytic etifoxine is hypothesized to act as a neurosteroidogenic agent via the 18-kDa translocator protein. In a placebo controlled design, we compared its steroidogenic effects with those of alpra...
07
DOI 10.1055/a-2894-5577
Open DOI
Pipamperone metabolism by various recombinant cytochrome preparations
The evaluation of pharmacokinetic interactions is based on the knowledge of enzymatic metabolization by cytochrome 450 enzymes or cellular transport processes. Research on the metabolism of pipamperone, an antipsychotic of the butyrophen...
08
DOI 10.1055/a-2924-4384
Open DOI
Lithium Prescription in Unipolar Depression: Findings from a Nationwide Greek Cohort Study
Introduction Lithium is a well-evidenced option for treatment-resistant unipolar depression. However, its use has globally declined over the past two decades and there is little evidence on exactly how unpopular the unipolar augmentation...
09
DOI 10.1055/a-2899-9948
Open DOI
Guideline adherence in patients with long-term schizophrenia in Germany: Focus on clozapine and electroconvulsive therapy
Previous studies suggest a problem in the care of long-term patients in psychiatry, i.e., patients with long hospitalizations and no indication for acute inpatient treatment. Long stays are often associated with treatment resistance, for...
10
DOI 10.1055/a-2869-0635
Open DOI
Efficacy and tolerability of nutraceuticals and phytotherapics for antipsychotic-induced weight gain in schizophrenia spectrum disorders: Systematic review and meta-analysis.
Antipsychotic drugs frequently cause metabolic complications in people with schizophrenia spectrum disorders, increasing cardiovascular morbidity and contributing to premature mortality; nutraceutical and phytotherapeutic agents may offe...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Articles in English or German; summaries in both languages.
Continues: Pharmacopsychiatria.